Contrastive analysis on the safety of brand and generic nebivolol: a real-world pharmacovigilance study based on the FDA adverse event reporting system

Contrastive analysis on the safety of brand and generic nebivolol: a real-world pharmacovigilance study based on the FDA adverse event reporting system

Background: The equivalence of generic drugs to their brand-name counterparts is a controversial issue. Current literature indicates disparities between the generic nebivolol (GN) and the brand nebivolol (BN).Aim: The study is designed to investigate the safety difference between GN and BN and provi...

Full description

Bibliographic Details
Main Authors: Hongli Wang, Guizun Zhong, Huanhuan Ji, Siqi Chen, Qinqin Xie, Zhengze Shen, Yuntao Jia
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
nebivolol
original drug
generic drug
FDA adverse event reporting system
disproportional analysis
adverse reaction
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1280201/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1280201/full

Similar Items